News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Mochida Pharmaceuticals Completes Early Phase II Clinical Trial Of Epadel Indicated For Alzheimer’s Disease
December 15, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Tokyo (JCN) Dec 15, 2005 - Mochida Pharmaceutical has completed an early phase II clinical trial of Epadel, which is targeted at Alzheimer's disease. Epadel is the company's proprietary agent used in the treatment of hyperlipemia.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Asia
MORE ON THIS TOPIC
Clinical research
Vertex opens up larger kidney disease opportunity with mid-stage readout
September 22, 2026
·
3 min read
·
Annalee Armstrong
Diabetes
Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial
September 22, 2026
·
2 min read
·
Annalee Armstrong
Manufacturing
Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
September 21, 2026
·
2 min read
·
Nick Paul Taylor
Sponsored by AGC Biologics
Beyond Random Integration: Transposase cell line development shortening timeline & boosting titers
September 21, 2026
·
7 min read
·
AGC Biologics
